REGULATION OF IMMUNE RESPONSES BY FC PORTION OF ANTIBODY

抗体 FC 部分对免疫反应的调节

基本信息

项目摘要

The long-term goal of this research is to investigate the mechanism in human B-\and T-cell activation. Studies employing human peripheral blood, tonsil, and splenic lymphocytes indicate that Fc fragments derived from papain digestion, p'Fc fragments derived from plasmin digestion, aggregated immunoglobulin, and immune complexes are potent polyclonal activators. Studies designed to ascertain the cell-cell interaction requirements have revealed that both monocytes and T cells are required for the generation of polyclonal antibody. The role of the monocyte is to enzymatically cleave the Fc fragments into Fc subfragments which then induce Ig secretion. The role of the T cell is to secrete a B-cell differentiation factor (CDF) which in conjunction with Fc subfragments drive B cells to secrete Ig. The active region of the Fc fragment has been localized to approximately the first 24 residues of the CH3 domain [Eu IgG1 335-258] of the molecule. Based on this sequence a 23 residue peptide (p23) was synthesized and found to be a potent lymphocyte activator. Fc fragments derived from a human IgG1 myeloma protein are capable of augmenting the in vitro anti-SRBC response of human PBL. The addition of Fc to cultures of human PBL along with SRBC resulted in a pronounced enhancement of the primary in vitro anti-SRBC response. Augmentation of the immune response is mediated by Fc and not the result of an artifact due to the addition of extraneous protein to culture because neither intact IgG1 nor Fab fragments possess any adjuvant properties. Over the past year, attempts have been made to establish a more relevant in vitro antigen-specific response model. We are currently investigating whether the in vitro antibody response to influenza by human PBL would be suitable. The choice of influenza as the test antigen is ideal since it represents an anamnestic response. (CS)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDWARD L. MORGAN其他文献

EDWARD L. MORGAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDWARD L. MORGAN', 18)}}的其他基金

PSYCONEUROIMMUNE INTERACTIONS IN IMMUNOSUPPRESSION
免疫抑制中的心理神经免疫相互作用
  • 批准号:
    2248946
  • 财政年份:
    1994
  • 资助金额:
    $ 9.54万
  • 项目类别:
PSYCONEUROIMMUNE INTERACTIONS IN IMMUNOSUPPRESSION
免疫抑制中的心理神经免疫相互作用
  • 批准号:
    2248948
  • 财政年份:
    1994
  • 资助金额:
    $ 9.54万
  • 项目类别:
PSYCONEUROIMMUNE INTERACTIONS IN IMMUNOSUPPRESSION
免疫抑制中的心理神经免疫相互作用
  • 批准号:
    2248947
  • 财政年份:
    1994
  • 资助金额:
    $ 9.54万
  • 项目类别:
HUMAN COMPLEMENT C5A--INFLAMMATION AND IMMUNOMODULATION
人类补体 C5A——炎症和免疫调节
  • 批准号:
    2067404
  • 财政年份:
    1993
  • 资助金额:
    $ 9.54万
  • 项目类别:
HUMAN COMPLEMENT C5A--INFLAMMATION AND IMMUNOMODULATION
人类补体 C5A——炎症和免疫调节
  • 批准号:
    2067403
  • 财政年份:
    1993
  • 资助金额:
    $ 9.54万
  • 项目类别:
HUMAN COMPLEMENT C5A--INFLAMMATION AND IMMUNOMODULATION
人类补体 C5A——炎症和免疫调节
  • 批准号:
    3147618
  • 财政年份:
    1993
  • 资助金额:
    $ 9.54万
  • 项目类别:
ANAPHYLATOXIN-MEDIATED REGULATION OF THE IMMUNE RESPONSE
过敏毒素介导的免疫反应调节
  • 批准号:
    3129093
  • 财政年份:
    1983
  • 资助金额:
    $ 9.54万
  • 项目类别:
REGULATION OF IMMUNE RESPONSES BY THE FC PORTION OF AB
AB 的 FC 部分对免疫反应的调节
  • 批准号:
    3071441
  • 财政年份:
    1981
  • 资助金额:
    $ 9.54万
  • 项目类别:
IMMUNE FUNCTION REGULATION BY THE FC PORTION OF ANTIBODY
抗体 FC 部分对免疫功能的调节
  • 批准号:
    3169346
  • 财政年份:
    1981
  • 资助金额:
    $ 9.54万
  • 项目类别:
IMMUNE FUNCTION REGULATION BY THE FC PORTION OF ANTIBODY
抗体 FC 部分对免疫功能的调节
  • 批准号:
    3169348
  • 财政年份:
    1981
  • 资助金额:
    $ 9.54万
  • 项目类别:

相似国自然基金

IL-15调控CD8+CD57+T淋巴细胞抗肿瘤免疫应答的作用和机制研究
  • 批准号:
    82303170
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
GBP4调控T淋巴细胞所致早发冠心病的机制研究
  • 批准号:
    82370336
  • 批准年份:
    2023
  • 资助金额:
    47 万元
  • 项目类别:
    面上项目
CD40/CD40L通路激活CD8+毒性T淋巴细胞调控TED眼眶组织重塑的机制研究
  • 批准号:
    82371105
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
基于神经重编程探究电针围刺促进乳腺癌CD8+T淋巴细胞募集的抗肿瘤机制
  • 批准号:
    82305396
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Orthogonal CRISPR GEMMs
正交 CRISPR GEMM
  • 批准号:
    10639698
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
Modulation of NOD Strain Diabetes by ENU-Induced Mutations
ENU 诱导突变对 NOD 菌株糖尿病的调节
  • 批准号:
    10642549
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
Project 2 - Verification and Molecular Mechanisms of T1D Modifier Mutations
项目2-T1D修饰突变的验证和分子机制
  • 批准号:
    10642554
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
Generation of highly differentiated NK cells to act in synergy with broadly neutralizing antibodies to reduce the SIV reservoir and establish viral control in absence of ART
生成高度分化的 NK 细胞,与广泛中和抗体协同作用,减少 SIV 储存库,并在没有 ART 的情况下建立病毒控制
  • 批准号:
    10883005
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
HSV-1 Encoded MicroRNAs in the Pathogenesis and Treatment of Ocular Herpes
HSV-1 编码的 MicroRNA 在眼疱疹发病机制和治疗中的作用
  • 批准号:
    10569577
  • 财政年份:
    2022
  • 资助金额:
    $ 9.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了